Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model
© Springer-Verlag 2011
Received: 22 April 2011
Accepted: 29 June 2011
Published: 13 July 2011
Celecoxib, a selective cyclooxygenase-2 inhibitor, has shown potential anticancerous activity against majority of solid tumors especially on patients with colon cancer. However, associations of serious side effects limit the usage of celecoxib in colon cancer treatment. To address this issue and provide an alternative strategy to increase the efficacy of celecoxib, liposomal formulation of celecoxib was prepared and characterized. Anticancer activity of liposomal celecoxib on colon cancer cell HCT 15 was evaluated in vitro. Furthermore, tumor inhibition efficiency by liposomal celecoxib was studied on 7,12-dimethyl benz(a)anthracene (DMBA)-induced tumor in rat model. In order to elucidate the antioxidant activity of celecoxib-loaded liposomes, antioxidant superoxide dismutase (SOD) generation and lipid peroxide (LPx) formation in both liver and kidney tissues were examined. Characterization of the formed unilamellar liposomes revealed the formation of homogeneous suspension of neutral (empty) or anionic (celecoxib-loaded) liposomes with a well-defined spherical shape which have a mean size of 103.5 nm (empty liposome) and 169 nm (liposomal celecoxib). High-performance liquid chromatography (HPLC) analysis and hemolytic assay demonstrated 46% of celecoxib entrapment efficiency and significantly low hemolysis, respectively. Liposomal celecoxib exhibited dose-dependent cytotoxicity and apoptotic activity against HCT 15 cells which are comparable to free celecoxib. In vivo study demonstrated inhibition of tumor growth. Biochemical analysis of the liposomal celecoxib-treated group significantly inhibited the LPx formation (oxygen-free radicals) and increased the activity of SOD. Our results present the potential of inhibiting colon cancer in vitro and DMBA-induced tumor in rat model in vivo by liposomal celecoxib.
Chemotherapeutic agents used for cancer treatment have large volume of distribution upon intravenous administrations which result in narrow therapeutic index, unsolicited drug distribution, and high level of toxicity in healthy tissues (Turanek et al. 2009). In the recent years, several research works have manipulated pharmacokinetic and biodistribution properties of drug-loaded lipid/polymer nanocarriers to improve the anticancer activity (Yang et al. 2007; Lu et al. 2008; Nakano et al. 2008; Hiremath et al. 2009). The nanocarriers should be long circulating in blood in order to passively target tumor tissue through enhanced permeability and retention effect (EPR) (Katanasaka et al. 2008). Among the several nanocarriers, liposomes are extensively used for drug delivery and modeling of cell membrane to elucidate their endocytosis mechanisms (Nakano et al. 2008; Hiremath et al. 2009). Liposomes are sophisticated and handy nanodelivery systems which facilitate targeted drug delivery, thereby reducing organ-specific side effects of several anticancer agents (Abu Lila et al. 2009). Liposomal formulation of hydrophobic drugs has been reported to overcome the solubility and the solvent-induced side effects (Katanasaka et al. 2008). In vivo studies using liposomal formulations have also been reported to reduce anticancer agent-mediated toxicities (Storm et al. 1987; Turanek et al. 2009). Indeed, the liposomal formulation of anticancer agents approved for medical applications are daunorubicin (DaunoXome) and DOX (Doxil; Drummond et al. 1999). Liposomal formulation of paclitaxel and doxorubicin are the prime examples for enhanced solubility and reduced cardiotoxicity profile, respectively (Yang et al. 2007; Tan et al. 2010).
Among the different types of cancer, colon cancer is the second leading cause of cancer-related deaths worldwide. According to the World Health Organization (WHO) report, colon cancer accounts for 677,000 deaths per year (Auman et al. 2008). Commonly used first-line chemotherapeutic regimens for colon cancer involve combination of infusional 5-fluorouracil, leucovorin, and oxaliplatin with bevacizumab or infusional 5-fluorouracil, leucovorin, and irinotecan with bevacizumab (Gaiser et al. 2008). Despite the chemotherapy, solubility and organ-specific toxicity associated with several anticancer agents necessitate designing effective formulation to treat colon cancer.
2 Materials and methods
DSPC (1,2-distearoyl-sn-glycero-phosphatidylcholine), MTT (3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide), PI (propidium iodide), DAPI (4′,6-diamidino-2-phenylindole), reduced glutathione, DTNB (5,5-dithiobis(2-nitrobenzoic acid)), RNase (ribonuclease), and DMBA were obtained from Sigma Aldrich, USA. Synthetic grade of methanol and chloroform was obtained from Merck, India. Celecoxib was generously provided by Aarthi Drug Ltd, Mumbai, India. HEPES was obtained from Sisco Research Labs. Animal food pellet was supplied by Hindustan Lever Ltd, Mumbai, India. Phosphotungstic acid, thiobarbituric acid, trichloroacetic acid, acetic acid, sodium salicylate, and EDTA were purchased from the Himedia Chemicals (Pvt) Ltd, Mumbai, India. Ascorbate, FeCl3, sodium tungstate, sodium nitrate, methanol, and other reagents were of analytical grade. All other chemicals were of highest possible grade and obtained from commercial sources. The chemicals were used as supplied.
2.1 Cell culture and conditions
Human colon cancer cell line HCT 15 (National Centre for Cell Science (NCCS), Pune, India) was grown as adherent culture in RPMI 1640 medium (Himedia, India) supplemented with 10% FBS (Gibco®, Invitrogen, India), 2 mM l-glutamine, 100 units/ml penicillin, and 0.1 mg/ml streptomycin (Himedia, India) at 37°C and 5% CO2 in air. After the cells became 80% confluent (usually after 3 days), they were trypsinized (0.25% trypsin + 0.1% EDTA), centrifuged (Heraeus table top centrifuge E003) and suspended in medium. For subsequent experiments, the cells were seeded in 96-well plate, cover slip, and 60 mm Petri dish.
2.2 Preparation of liposomal celecoxib
Empty and celecoxib-loaded liposomes were prepared using modified thin film method as stated by Bangham et al. (Sadzuka et al. 2005). Briefly, phospholipid (DSPC) and celecoxib were dissolved together in methanol with the lipid to drug ratio of 4:1 w/w in a round-bottom flask. The solvent was then evaporated in a Bǜchii rotoevaporator to form a thin film along the wall of the flask. It was attached to high vacuum for 2 h to remove any traces of the solvent. To the dry film, HEPES buffered saline (10 mM HEPES and 150 mM NaCl) was added and agitated above the gel transition temperature of DSPC. The liposomal suspension was then freeze-thawed for five times by alternately freezing in liquid nitrogen and then subsequently bringing above its gel transition temperature. The formed multilamellar vesicles were then sonicated using ultra sonic probe (Cole Parmer CP-18) for 20 min to obtain an optically clear solution. The resultant unilamellar vesicles were then centrifuged for 15 min at 4°C and 10,000 rpm to remove phospholipid residue and titanium impurity. The visibly clear supernatant was withdrawn and stored at 4°C. The liposomal solution was ultracentrifuged (Sorvall Ultra Pro 80) at 120,000×g force at 4°C for 2 h to remove any unencapsulated celecoxib. Supernatant was discarded, and pellet was resuspended in HEPES buffered saline (pH 7.0) to a final phospholipid concentration of 2 mg/ml. All experiments were performed with freshly prepared liposomes.
2.3 Analysis of liposomes using AFM and TEM
Vesicle formation and morphology of liposomes were analyzed using atomic force (AFM, Veeco CPII, USA) and high-resolution transmission electron (HRTEM, JEOL JEM) microscopies. The liposome samples were diluted (tenfold with 10 mM HEPES buffer saline), added to a freshly cleaved mica sheet and allowed to remain in contact for 5 min. From the mica sheet, excess sample was removed, dried, and analyzed using tapping mode AFM (Li et al. 2008; Nakano et al. 2008). The tapping mode settings were as follows—0.5 Hz scan rate, resolution of 256 × 256 data points per scan, AV-shaped silicon nitride cantilever (MMP-11123, Veeco Instruments Inc., USA) having spring constant 40 N/m, length 115–135 μm, and radii of curvature <10 nm.
For transmission electron microscopy (TEM) analysis, the diluted liposomes were applied to carbon-coated copper grids and negatively stained with 1% ammonium molybdate solution (pH 7.0). The excess of liposomes were removed from the grid and dried for further analysis. Three grids were prepared for each sample.
2.4 Particle size and zeta potential measurement
The mean particle size, polydispersity index, and zeta potential of empty and celecoxib-loaded liposomes were measured by DLS (dynamic light scatter, Nano-ZS, Malvern Instrument, UK). HEPES buffered saline diluted liposome samples were backscattered by a helium-neon laser (633 nm) at an angle of 173° and temperature of 25°C (Zhang et al. 2008; Turanek et al. 2009; Yang et al. 2009). Mean surface charge was calculated from samples taken in triplicate and analyzed based on Gaussian size distribution.
2.5 Entrapment efficiency
A known volume of liposomal celecoxib was diluted into suitable concentration with methanol. It was then bath-sonicated to disrupt the liposomes and release the encapsulated celecoxib. The amount of encapsulated celecoxib in liposomes was quantitatively determined using reverse phase HPLC (Shimadzhu LC-10AD pump liquid chromatograph, Diamonsil® C-18 column, 250 mm × 4.6 mm, 5 μm) using methanol/water (75:25 v/v) as mobile phase (Saha et al. 2002). The analysis was performed at 20 μl injection, 1.25 ml min−1 of flow rate, and UV detector at 250 nm (Baboota et al. 2007). Calibration curve was constructed using celecoxib in the concentration range of 0–150 μM. Dilution factor was taken into consideration for calculating the entrapment efficiency of celecoxib in liposomes. The analysis was done in triplicate, and values were reported as mean±SD. The percentage of celecoxib entrapped in liposomes was calculated as: Entrapment efficiency (%) = (Amount of encapsulated celecoxib/Total amount of celecoxib) × 100.
2.6 Hemocompatibility study
Free celecoxib, empty, and celecoxib-loaded liposomes were diluted in 10 mM HEPES buffer saline to desired concentrations. Hemocompatibility of different samples were analyzed using a previous protocol with some modification (Katanasaka et al. 2008). In brief, blood was collected from 6-week-old BALB/c male mice and centrifuged (1,500×g for 5 min at 4°C using Ficoll density gradient solution) to obtain red blood cells (RBC). Collected RBC pellet was diluted with 20 mM HEPES buffered saline (pH 7.4) to give a 5% v/v solution. The RBC suspension was added to HEPES buffer saline, 1% Triton X-100, free celecoxib, and empty and celecoxib-loaded liposomes. All samples were incubated at 37°C for 30 and 60 min. After incubation, the samples were centrifuged at 12,000 rpm at 4°C, and supernatants were transferred to a 96-well plate. Hemolytic activity was determined by measuring the absorption at 570 nm (Bio-rad, microplate reader, model 550, Japan). Control samples of 0% lysis (in HEPES buffer) and 100% lysis (in 1% Triton X-100) were employed in the experiment (Guggi et al. 2004). The study was performed in triplicate. Hemolytic effect of each sample was expressed as percentage of cell lysis relative to the untreated control cells (% control) defined as: [(OD 570 nm sample)/(OD 570 nm control)] × 100, where optical density was abbreviated to OD.
2.7 Cell proliferation assay
Cytotoxicity of free celecoxib, empty, and celecoxib-loaded liposomes on colon cancer cells HCT 15 was determined by cell proliferation assay as described previously (Yang et al. 2007). Briefly, HCT 15 cells in exponential growth phase were seeded onto 96-well plates at a density of 5 × 103 cells per well in 0.1 ml medium. Cells were allowed to adhere and grow for 24 h at 37°C in an incubator (Heraeus Hera Cell). Then, the medium was aspirated and replaced with 0.1 ml fresh medium containing various concentrations of free celecoxib, empty, and celecoxib-loaded liposomes. Control well was treated with equivalent volume of celecoxib-free media. After 72 h of incubation, the medium was removed, and cell viability was determined using a conventional MTT dye reduction assay. Then, 100 μl of 1 mg/ml MTT reagent was added to each well. After 4 h incubation, unreduced MTT solution was discarded. Then, 100 μl of dimethyl sulfoxide was added into each well to dissolve purple formazan crystals which was reduced from MTT by active mitochondria of viable cells. Plate was shaken for 20 min, and formazan dye was measured spectrophotometrically using a microplate reader. The experiment was performed in triplicate. The cytotoxicity of each treatment was expressed as percentage of cell viability relative to the untreated control cells (% control) defined as [(OD 550 nm treated cells)/(OD 550 nm control cells)] × 100, where optical density is abbreviated to OD.
2.8 Morphological analysis
HCT 15 cells were grown at a density of 3 × 104 in Petri dishes and treated with absence (control) or presence of IC50 concentrations of free celecoxib, liposomal celecoxib, and empty liposomes (volume equivalent to liposomal celecoxib) for 48 h. After incubation, morphological changes were observed under phase contrast microscope (Leica, ×20; Caddeo et al. 2008).
Furthermore, morphological analysis of cancer cells using high-resolution scanning electron microscope (SEM) was performed to obtain a clear insight regarding cell membrane extensions (filopodia and lamellipodia; Venkatesan et al. 2010). HCT 15 cells grown on a sterile cover slip were treated with free celecoxib (IC50), liposomal celecoxib (IC50), and empty liposomes (equivalent to volume liposomal celecoxib) for 48 h. Cells were washed thrice in 0.1 M cacodylate buffer (pH 7.4) and post-fixed using ice-cold 1% OsO4 for 30 min. Cells were then dehydrated with grades (50%, 70%, 95%, and 100%) of ethanol. Next, the cover slips were placed in HMDS (1,1,1,3,3,3-hexamethyl disilazane) for 5 min to overcome drying effect. Samples were then air-dried at room temperature, mounted on a stub, and placed in vacuum chamber of SEM gold coating apparatus for gold coating (2.5 kV, 20–25 mA for 120 s). The morphogram of the HCT 15 cells was then observed using SEM (JEOL JSM-5800 Japan) at 20 kV acceleration voltage (Hodges 1970; Glaser et al. 1977).
2.9 Cell cycle analysis
HCT 15 cells at a density of 2 × 105 was cultured in 60 mm Petri dishes for 24 h and then treated with free celecoxib (IC50), empty liposomes (equivalent to volume liposomal celecoxib), and celecoxib-loaded liposomes (IC50) for 48 h. In this study, medium and empty liposome-treated cells were used as reference control and blank formulation, respectively. After incubation, HCT 15 cells were centrifuged at 1,200 rpm for 5 min at 4°C. The cell pellet was suspended in 5 ml of PBS and then centrifuged at 1,200 rpm for 10 min at 4°C. The supernatant was discarded, and the pellet was fixed with 2 ml of ice-cold ethanol solution (70% v/v) at 4°C overnight. Fixed cells were centrifuged at 1,200 rpm for 10 min at 4°C, and the pellet was incubated with PI mixture (10 mg/ml RNase, 20 μg/ml PI in cold PBS) for 30 min at 37°C. DNA content analysis was carried out on a FACS Calibur (BD Bioscience) flow cytometer (Celia et al. 2008). The data obtained were processed for cell cycle analysis with the Cell Quest Pro software package.
2.10 Nuclear analysis
Apoptosis of HCT 15 cells treated with free celecoxib, empty, and celecoxib-loaded liposomes was analyzed by epi-fluorescence microscopy. HCT 15 cells were seeded in six-well plates containing a cover slip with 2 × 105 cells per well and cultured at 37°C for 24 h. Cells were then treated with free celecoxib (IC50), celecoxib-loaded liposomes (IC50), and empty liposomes (equivalent to volume liposomal celecoxib) and culture medium (control) for 48 h. Cells were then fixed (2% ice-cold paraformaldehyde in PBS for 20 min), permeabilized (0.1% Triton X-100), stained (0.2 μg/ml DAPI in PBS for 15 min), and washed twice with PBS. Cover slips were mounted onto glass slides and examined using a fluorescence microscope (Leica DMR, ×20). Apoptotic cells were evaluated based on nuclear morphology, chromatin condensation, and fragmentation (Caddeo et al. 2008; Danhier et al. 2009).
2.11 Inhibition of DMBA-induced tumor in rat model
Female Wistar rats (6-week-old and 100 g of weight) were divided into five groups containing six rats each. Rats were maintained at 28 ± 1°C, relative humidity at 60% (each 12 h of light and dark cycle). These rats were fed with standard food pellets (diet composition, broken wheat-moisture 9.0%, crude protein 11.5%, crude fat 1.9%, crude fiber 4.0%, Ash 0.2%, and nitrogen-free extract 73.4%) and tap water ad libitum. The experimental procedures were carried out with prior approval from animal ethical committee at the university.
2.11.1 Experimental design, tumor induction, and inhibition
Rat tumors were induced by DMBA injection (Huggins et al. 1961; Singh and Shukla 1998; Malejka-Giganti et al. 2000; Samy et al. 2006). DMBA (250 mg/kg) dissolved in 1 ml of vehicle (0.5 ml of sunflower oil plus 0.5 ml of PBS saline) was injected subcutaneously near either side of mammary glands. After 90 days of injection, tumor yield and size were stabilized.
Shows the experimental design, dosage, and treatment
Tumor induction (DMBA treatment 250 mg/ml/kg rat)
Tumor inhibition (treatment: three times in the first 5 days through tail vein injection, 1 day spaced between two administrations)
Cancer + celecoxib
Celecoxib (100 μg/kg diluted in PBS)
Cancer + empty liposome
Empty liposome (equivalent volume of liposomal celecoxib) in PBS
Cancer + liposomal celecoxib
Equivalent to celecoxib concentration 100 μg/kg in PBS
2.12 Biochemical analysis of antioxidants
The following biochemical measurements were carried out in the rat liver and kidney tissues. The organs were excised and removed from the experimental groups for the estimation of antioxidant enzymes. Tissues were washed thoroughly with ice-cold normal phosphate buffer saline, pH 7.2 (PBS, 0.9%) and cut into small pieces with a heavy-duty blade. Tissues were homogenized by a glass homogenizer tube in cold PBS, and centrifuged at 20,000 rpm for 10 min, and the supernatant was diluted with PBS up to a final protein concentration. Effects of liposomal celecoxib on activities of SOD generation and LPx were estimated in the liver and kidney tissues of treated and control rats.
2.12.1 SOD radical scavenging activity
SOD activity was assessed by the Nitroblue tetrazolium reduction method (Samy et al. 2006). Approximately, a known protein concentration of tissue supernatant was added to a reaction mixture containing 0.1 mM EDTA (200 μl), 0.12 mM riboflavin (50 μl), and 0.6 M phosphate buffer (pH 7.8) in a final volume of 3 ml. The optical density was measured at 560 nm.
2.12.2 Inhibition of LPx formation
Induction by Fe3+/ascorbate system: the reaction mixture containing rat liver and kidney homogenate (0.1 ml, 50% w/v) in Tris–HCl (30 mM), ferrous ammonium sulfate (0.16 mM), ascorbic acid (0.06 mM), and the reaction mixture was incubated for 1 h at 37°C, and the resulting thiobarbituric reacting substances were measured (Samy et al. 2006). Briefly, a 0.4 ml aliquot of the reaction mixture was treated with sodium dodecyl sulfate (0.2 ml, 8%), thiobarbituric acid (1.5 ml, 0.8%), and acetic acid (1.5 ml, pH 3.5), made up to a total volume of 4 ml by adding distilled water, and then kept in a water bath at 95°C for 1 h. After cooling, 1 ml of distilled water and 5 ml of n-butanol/pyridine (15:1 v/v) were added. The organic layer was separated after shaking and centrifugation. LPx activity was measured in terms of thiobarbituric acid formation and the color intensity measured spectrophotometrically at 530 nm.
2.13 Statistical analysis
All the statistical analysis was performed by Graphpad Prism 5 software. Data were presented using mean±SD. The statistical significance was determined by using one-way analysis of variance (ANOVA). ***P < 0.001 and **P < 0.05 were considered significant.
3 Results and discussion
3.1 Analysis using AFM and TEM
The prepared liposomes appeared semi-transparent and visible sky-blue opalescent dispersion. Previous studies have reported that nature of phospholipid composition in liposomal carrier have influence on its stability, entrapment efficiency, and blood circulation time (Nakano et al. 2008). Furthermore, rigidity of liposome particles was attributed to phase transition temperature (55°C) of DSPC (Egawa and Furusawa 1999; Nakano et al. 2008). Our AFM images of both empty and celecoxib-loaded liposomes indicate spherical-shaped homogeneous particles (Fig. 1b–e).
In addition, TEM analysis is a semi-quantitative technique, which provides enough information on morphology of liposomes (Zhang et al. 2008). Under TEM analysis, surface morphology is very distinct with well-formed liposomes (Fig. 1f, g). The inner areas of both the liposomes appeared gloomy which might be attributed to dense packing of the lipid bilayer vesicles. The results displayed discrete, homogeneous, round particles with size of 125 and 170 nm for empty and celecoxib-loaded liposomes, respectively.
3.2 Particle size and zeta potential measurement
The DLS analysis showed mean particle size of 103.5 and 169 nm for empty and celecoxib-loaded liposomes, respectively. The results indicate formation of large unilamellar liposome formulation prepared by modified thin film method. Polydispersity index describes relative error between curve fit and experimental values, which suggests homogeneity of colloidal suspension. Polydispersity index greater than 0.7 indicates that sample has a very broad size distribution (Caddeo et al. 2008). In our study, polydispersity index of empty and celecoxib-loaded liposomes was determined as 0.604 and 0.409, respectively, which indicate formation of homogeneous liposomes.
The zeta potential is a good index of degree of repulsive interactions between colloidal particles. It depends on particle composition, especially on the lipid concentration and incorporated drug (Katanasaka et al. 2008; Jung et al. 2009). Surface charge (zeta potential) measurement of empty and celecoxib-loaded liposomes have shown 0.11 and −8.22 mV, respectively. Since the phospholipid is almost neutral in charge, negative surface charge of celecoxib-loaded liposomes indicates likely association of celecoxib in liposomes. Furthermore, high negative charge of the liposomal celecoxib leads to high repulsive force between particles which might prevent aggregation liposome particles.
3.3 Entrapment efficiency of liposomes
The amount of celecoxib encapsulated in liposomes was determined by HPLC analysis. The study result shows 46% of entrapment efficiency, which indicates good incorporation potential of the prepared liposomes.
3.4 Hemocompatibility study
Intravenous administration of a drug is limited by properties like solubility, hemolysis, and toxicity. Liposomal formulations of hydrophobic drugs have been reported to overcome the solubility problem and hemolytic activity of free drugs (Guggi et al. 2004; Katanasaka et al. 2008). Hemolytic assay was performed to examine interaction between the anionic liposomal celecoxib and anionic red blood cell membrane (Katanasaka et al. 2008). The membrane-damaging property of liposomes was determined by measuring released hemoglobin.
3.5 Cell proliferation assay
Compared with the free paclitaxel, liposomal formulation of paclitaxel has demonstrated enhanced solubility and cytotoxicity against variety of cancer cell lines (Yang et al. 2007). In this study, cytotoxicity of liposomal celecoxib and free celecoxib was investigated on HCT 15 cells using widely established metallothionein (MTT) assay. Both free celecoxib and liposomal celecoxib have significantly inhibited HCT 15 cells proliferation in a dose-dependent manner. The IC50 value of the free celecoxib on HCT 15 cell was a little lower (102.71 μM) than liposomal celecoxib (IC50 127.67 μM; Venkatesan et al. 2010). Furthermore, free celecoxib displayed low cell viability compared with liposomal celecoxib which might be due to higher intracellular uptake of free celecoxib by HCT 15 cells (Fig. 2b; Caddeo et al. 2008; Celia et al. 2008; Abu Lila et al. 2009). In contrast, low cytotoxicity mediated by liposomal celecoxib might be ascribed to low intracellular uptake resulting from electrostatic repulsion between cells (anionic) and liposomes (anionic), and slow release of celecoxib. This results in reduced intracellular concentration of celecoxib in the cells. As expected, the empty liposomes did not show growth inhibitory activity on HCT 15 cells at volume equivalent to the celecoxib-loaded liposomes (data not shown). This observation substantiates that the cytotoxicity of liposomal celecoxib on HCT 15 cells is due to the celecoxib released from liposomes than the carrier itself (phospholipid).
3.6 Morphological analysis
SEM is a vital tool to analyze surface and morphological features of cancer cells. Many researchers have used SEM for morphological analysis of normal and cancer cells (Jacobs et al. 1976). SEM analysis of osteosarcoma has revealed a close relationship between cell morphology and its function (Docheva et al. 2008). Previous study of AEE788- and/or celecoxib-mediated morphological changes used SEM to evaluate the anticancer activity. Anticancer agent-mediated morphological changes in cancer cell may potentially be valuable for cancer chemotherapy (Venkatesan et al. 2010). The study was aimed to analyze morphology of celecoxib, empty, and celecoxib-loaded liposome-treated HCT 15 cells. From the obtained SEM image (Fig. 3b), the control HCT 15 cells have shown highly dynamic, flat cell with filamentous lateral cell membrane extensions (filopodia and lamellipodia). In contrast, free celecoxib- and liposomal celecoxib-treated HCT 15 cells have demonstrated shrunken morphology, small ruffles, irregular cytoplasm detached from substratum, and loss of cell membrane extensions. However, empty liposome-treated HCT 15 cells showed insignificant changes in cell morphology. It was observed that the cytotoxicity of liposomal celecoxib on HCT 15 cells was equivalent to free celecoxib. All the above results suggest the liposomes nanocarriers could be a promising choice for celecoxib delivery without loss of its therapeutic efficacy.
3.7 Cell cycle analysis
3.8 Epi-fluorescence microscopic analysis
The majority of anticancer agents including celecoxib interact with nuclear DNA to cause DNA damage thus preventing cell proliferation and inducing apoptosis (Wei et al. 2008; Danhier et al. 2009; Jung et al. 2009; Munoz-Bonilla et al. 2009; Yuan et al. 2010). The control and treated HCT 15 cells were stained with DAPI. The control HCT 15 cells displayed normal, round nuclear morphology, and homogenous fluorescence without any DNA fragmentation. In a similar way, the empty liposome-treated HCT 15 cells have also displayed no sign of DNA damage (Fig. 4b). This further substantiates biocompatibility of the liposomal carrier. Conversely, free celecoxib- and liposomal celecoxib-treated HCT 15 cells have displayed typical morphological characteristics of apoptosis which include shrunken nuclear size, chromatin condensation, and much brighter nuclear fragmentation compared with control. The ability of liposomal celecoxib to induce apoptosis suggests that the liposomalization did not affect apoptosis induction by celecoxib.
3.9 Inhibition of DMBA-induced tumor in rat model
3.10 Antioxidant activity
The effect of liposomal celecoxib on antioxidant enzymes of liver in DMBA-induced cancer in rats
3.45 ± 0.07*
0.79 ± 0.06*
1.27 ± 0.17
1.95 ± 0.27
Cancer + celecoxib
2.31 ± 0.29*
0.71 ± 0.06*
Cancer + empty liposome
1.39 ± 0.37
1.77 ± 0.47*
Cancer + liposomal celecoxib
3.35 ± 0.21*
1.09 ± 0.08*
The effect of liposomal celecoxib on antioxidant enzymes of kidney in DMBA-induced cancer in rats
1.55 ± 0.20*
1.70 ± 0.33*
0.69 ± 0.08
2.68 ± 0.24
Cancer + celecoxib
1.36 ± 0.12*
1.91 ± 0.40*
Cancer + empty liposome
1.09 ± 0.20*
2.15 ± 0.24*
Cancer + liposomal celecoxib
1.18 ± 0.08*
1.69 ± 0.18*
This study presents the preparation of liposomal celecoxib formulation and its effect on colon cancer in vitro and DMBA-induced cancer in vivo models. The fundamental outcome of the study is the successful formation of liposomal celecoxib with appropriate size, high entrapment efficiency, and hemocompatibility. Liposomal celecoxib- and free celecoxib-mediated cytotoxicity and apoptosis on HCT 15 cells are comparable. In addition, in vivo study exhibited more potent tumor growth inhibition by liposomal celecoxib than free celecoxib in rat tumor model without producing mortality and side effects. These results suggest that the liposome carriers may serve as an effective and safe vehicle for celecoxib delivery in colon cancer chemotherapy. This preliminary approach of liposome-mediated targeted delivery might overcome side effects caused by celecoxib. In this regard, detailed preclinical studies are required before advancing into human application.
This work was supported by funds from the School of Medical Science and Technology, Indian Institute of Technology, Kharagpur, India. We are grateful to Aarthi Drug Ltd., Mumbai, for generously providing celecoxib.
- Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H (2009) Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 137:8–14View ArticleGoogle Scholar
- Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, McLeod HL (2008) Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 44:1754–1760View ArticleGoogle Scholar
- Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F (2007) Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. PDA J Pharm Sci Technol 61:276–285Google Scholar
- Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ, Boven E (2008) Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol 75:427–437View ArticleGoogle Scholar
- Caddeo C, Teskac K, Sinico C, Kristl J (2008) Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 363:183–191View ArticleGoogle Scholar
- Celia C, Malara N, Terracciano R, Cosco D, Paolino D, Fresta M, Savino R (2008) Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine 4:155–166View ArticleGoogle Scholar
- Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, Preat V (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–17View ArticleGoogle Scholar
- Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW (2008) Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 7:897–904View ArticleGoogle Scholar
- Docheva D, Padula D, Popov C, Mutschler W, Clausen-Schaumann H, Schieker M (2008) Researching into the cellular shape, volume and elasticity of mesenchymal stem cells, osteoblasts and osteosarcoma cells by atomic force microscopy. J Cell Mol Med 12:537–552View ArticleGoogle Scholar
- Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743Google Scholar
- Egawa H, Furusawa K (1999) Liposome adhesion on mica surface studied by atomic force microscopy. Langmuir 15:1660–1666View ArticleGoogle Scholar
- Gaiser T, Becker MR, Habel A, Reuss DE, Ehemann V, Rami A, Siegelin MD (2008) TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci Lett 442:109–113View ArticleGoogle Scholar
- Glaser R, Mumaw V, Farrugia R, Munger B (1977) Scanning electron microscopy of the surfaces of hamster embryo cells transformed by herpes simplex virus. Cancer Res 37:4420–4422Google Scholar
- Guggi D, Langoth N, Hoffer MH, Wirth M, Bernkop-Schnurch A (2004) Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate. Int J Pharm 278:353–360View ArticleGoogle Scholar
- Hiremath PS, Soppimath KS, Betageri GV (2009) Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm 380:96–104View ArticleGoogle Scholar
- Hodges GM (1970) A scanning electron microscope study of cell surface and cell contacts of “spontaneously” transformed cells in vitro. Eur J Cancer 6:235–239View ArticleGoogle Scholar
- Hsiao PW, Chang CC, Liu HF, Tsai CM, Chiu TH, Chao JI (2007) Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol Appl Pharmacol 222:97–104View ArticleGoogle Scholar
- Huggins C, Grand LC, Brillantes FP (1961) Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 189:204–207View ArticleGoogle Scholar
- Jacobs JB, Arai M, Cohen SM, Friedell GH (1976) Early lesions in experimental bladder cancer: scanning electron microscopy of cell surface markers. Cancer Res 36:2512–2517Google Scholar
- Jung SH, Seong H, Cho SH, Jeong KS, Shin BC (2009) Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm 382:254–261View ArticleGoogle Scholar
- Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N (2008) Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett 270:260–268View ArticleGoogle Scholar
- Li Q, Peng J, Zhang GY (2008) Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33:1123–1128Google Scholar
- Ling YH, Liebes L, Zou Y, Perez-Soler R (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278:33714–33723View ArticleGoogle Scholar
- Lu Y, Li J, Wang G (2008) In vitro and in vivo evaluation of mPEG-PLA modified liposomes loaded glycyrrhetinic acid. Int J Pharm 356:274–281View ArticleGoogle Scholar
- Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S (2004) Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469–1478View ArticleGoogle Scholar
- Malejka-Giganti D, Niehans GA, Reichert MA, Bliss RL (2000) Post-initiation treatment of rats with indole-3-carbinol or beta-naphthoflavone does not suppress 7, 12-dimethylbenz[a]anthracene-induced mammary gland carcinogenesis. Cancer Lett 160:209–218View ArticleGoogle Scholar
- Mazhar D, Ang R, Waxman J (2006) COX inhibitors and breast cancer. Br J Cancer 94:346–350View ArticleGoogle Scholar
- Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW (2006) Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 5:329–336View ArticleGoogle Scholar
- Munoz-Bonilla A, Ibarboure E, Papon E, Rodriguez-Hernandez J (2009) Self-organized hierarchical structures in polymer surfaces: self-assembled nanostructures within breath figures. Langmuir 25:6493–6499View ArticleGoogle Scholar
- Nakano K, Tozuka Y, Yamamoto H, Kawashima Y, Takeuchi H (2008) A novel method for measuring rigidity of submicron-size liposomes with atomic force microscopy. Int J Pharm 355:203–209View ArticleGoogle Scholar
- Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG (2000) Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 28:514–521Google Scholar
- Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 297:638–645Google Scholar
- Sadzuka Y, Takabe H, Sonobe T (2005) Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release 108:453–459View ArticleGoogle Scholar
- Saha RN, Sajeev C, Jadhav PR, Patil SP, Srinivasan N (2002) Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography. J Pharm Biomed Anal 28:741–751View ArticleGoogle Scholar
- Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73:1318–1329View ArticleGoogle Scholar
- Samy RP, Gopalakrishnakone P, Ignacimuthu S (2006) Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Chem Biol Interact 164:1–14View ArticleGoogle Scholar
- Singh A, Shukla Y (1998) Antitumour activity of diallyl sulfide on polycyclic aromatic hydrocarbon-induced mouse skin carcinogenesis. Cancer Lett 131:209–214View ArticleGoogle Scholar
- Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJ (1987) Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res 47:3366–3372Google Scholar
- Tan ML, Friedhuber AM, Dunstan DE, Choong PF, Dass CR (2010) The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 31:541–551View ArticleGoogle Scholar
- Turanek J, Wang XF, Knotigova P, Koudelka S, Dong LF, Vrublova E, Mahdavian E, Prochazka L, Sangsura S, Vacek A, Salvatore BA, Neuzil J (2009) Liposomal formulation of alpha-tocopheryl maleamide: in vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice. Toxicol Appl Pharmacol 237:249–257View ArticleGoogle Scholar
- Venkatesan P, Das S, Krishnan MM, Chakraborty C, Chaudhury K, Mandal M (2010) Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques. Micron 41:247–256View ArticleGoogle Scholar
- Wei W, Ma GH, Hu G, Yu D, McLeish T, Su ZG, Shen ZY (2008) Preparation of hierarchical hollow CaCO3 particles and the application as anticancer drug carrier. J Am Chem Soc 130:15808–15810View ArticleGoogle Scholar
- Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD (2007) Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338:317–326View ArticleGoogle Scholar
- Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ (2009) A novel liposomal formulation of flavopiridol. Int J Pharm 365:170–174View ArticleGoogle Scholar
- Yuan Y, Liu C, Qian J, Wang J, Zhang Y (2010) Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. Biomaterials 31:730–740View ArticleGoogle Scholar
- Zhang L, Gao H, Chen L, Wu B, Zheng Y, Liao R, Jiang Y, He F (2008) Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett 269:26–36View ArticleGoogle Scholar